Lacktman, Ferrante Comment on Effort to Loosen Telemedicine Restrictions for Prescribing
14 January 2019
Partner Nate Lacktman and Senior Counsel TJ Ferrante were quoted in an mHealthIntelligence article, “ATA Presses DEA to Loosen Telemedicine Restrictions for Prescribing,” about a letter from the American Telemedicine Association urging federal authorities to loosen the reins on regulations that restrict mental health professionals from prescribing controlled substances via telehealth.
A blog post by the pair, who worked with the ATA on its recommendations, said the SUPPORT for Patients and Communities Act, which is designed to tackle the nation’s ongoing opioid abuse epidemic, was changed prior to passage to specifically require the U.S. Drug Enforcement Administration to gather public comments – thus enabling the ATA and others to make their opinions heard.
“The recommendations are designed to strike a balance between the country’s great need for additional behavioral health resources, commonly accepted clinical practices, the evolving landscape of telemedicine technologies, and DEA’s charge to protect the safety and wellbeing of citizens via drug diversion,” he wrote.
A blog post by the pair, who worked with the ATA on its recommendations, said the SUPPORT for Patients and Communities Act, which is designed to tackle the nation’s ongoing opioid abuse epidemic, was changed prior to passage to specifically require the U.S. Drug Enforcement Administration to gather public comments – thus enabling the ATA and others to make their opinions heard.
“The recommendations are designed to strike a balance between the country’s great need for additional behavioral health resources, commonly accepted clinical practices, the evolving landscape of telemedicine technologies, and DEA’s charge to protect the safety and wellbeing of citizens via drug diversion,” he wrote.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”